Keystone Heart is a medical device company developing and manufacturing cerebral embolic protection devices to reduce the risk of stroke, neurocognitive decline, and dementia caused by brain emboli associated with cardiovascular procedures.
The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation, and other cardiovascular procedures. The TriGuard product pipeline is designed to help interventional cardiologists, electrophysiologists, and cardiac surgeons preserve brain reserve in patients undergoing these procedures.
The TriGuard Cerebral Protection Device is placed via one of two femoral artery access ports typically used in TAVR, thereby eliminating the need for a third puncture site. It deploys rapidly, self-positions through a small 9F catheter, and provides stable, atraumatic protection with simple retrieval.